SCHEMBL10645663

SCHEMBL10645663

c1csc(CNc2ncnc3nc[nH]c23)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 7/20 1.00
▸ LMNA P02545 4/20 1.00
▸ TSHR P16473 5/20 0.63
▸ CYP1A2 P05177 2/20 0.63
▸ MAPK1 P28482 2/20 0.63
▸ CYP2D6 P10635 1/20 0.63
▸ CDK2 P24941 1/20 0.63
▸ ALOX15 P16050 2/20 0.61
▸ KDR P35968 2/20 0.61
▸ TP53 P04637 2/20 0.61
▸ MEN1 O00255 2/20 0.61
▸ KMT2A Q03164 2/20 0.61
▸ ADORA3 P0DMS8 1/20 0.61
▸ HIF1A Q16665 1/20 0.61
▸ HTT P42858 4/20 0.60
▸ NPC1 O15118 3/20 0.60
▸ RAB9A P51151 3/20 0.60
▸ KDM4E B2RXH2 1/20 0.60
▸ ALDH1A1 P00352 1/20 0.60
▸ RECQL P46063 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17933813 0.81 SMN1; SMN2 (1.00) SMN1; SMN2LMNACDK2NPC1
SCHEMBL14181334 0.80 SMN1; SMN2 (0.66) SMN1; SMN2LMNATSHRCYP1A2MAPK1
SCHEMBL30850588 0.80 SMN1; SMN2 (0.66) SMN1; SMN2LMNATSHRCYP1A2MAPK1
6-Benzylaminopurine SCHEMBL29349525 0.77 LMNA (1.00) SMN1; SMN2LMNATSHRCYP1A2MAPK1
6-Benzylaminopurine SCHEMBL37358 0.77 LMNA (1.00) SMN1; SMN2LMNATSHRCYP1A2MAPK1
6-Benzylaminopurine SCHEMBL8378682 0.76 LMNA (0.97) SMN1; SMN2LMNATSHRCYP1A2MAPK1
6-Benzylaminopurine SCHEMBL218733 0.76 LMNA (0.97) SMN1; SMN2LMNATSHRCYP1A2MAPK1
6-Benzylaminopurine SCHEMBL30241517 0.76 LMNA (0.97) SMN1; SMN2LMNATSHRCYP1A2MAPK1
SCHEMBL30402872 0.76 SMN1; SMN2 (0.61) SMN1; SMN2LMNATSHRCYP1A2MAPK1
6-Benzylaminopurine SCHEMBL11477809 0.76 LMNA (0.97) SMN1; SMN2LMNATSHRCYP1A2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240147927-A1 METHODS OF HIGH PRODUCTION OF POLYPHENOLS FROM RED LETTUCES AND USES THEREOF SIGNALCHEM PLANTECH CORPORATION (CA) 2024-05-09 — — US claimed
CN-117597021-A Method for high-volume production of polyphenols from red lettuce and use thereof 新格诺康植物技术公司 2024-02-23 — — CN claimed
EP-4297565-A1 METHODS OF HIGH PRODUCTION OF POLYPHENOLS FROM RED LETTUCES AND USES THEREOF Signalchem Plantech Corporation (CA) 2024-01-03 — — EP claimed
US-20240147927-A1 METHODS OF HIGH PRODUCTION OF POLYPHENOLS FROM RED LETTUCES AND USES THEREOF SIGNALCHEM PLANTECH CORPORATION (CA) 2024-05-09 — — US disclosed
CN-117597021-A Method for high-volume production of polyphenols from red lettuce and use thereof 新格诺康植物技术公司 2024-02-23 — — CN disclosed
EP-4297565-A1 METHODS OF HIGH PRODUCTION OF POLYPHENOLS FROM RED LETTUCES AND USES THEREOF Signalchem Plantech Corporation (CA) 2024-01-03 — — EP disclosed
US-4718936-A PLANT GROWTH REGULATORS BASF AKTIENGESELLSCHAFT (DE) 1988-01-12 — — US disclosed
EP-0154937-A2 6-(3-Thienylmethylamino)-purin, process for its preparation and its use BASF Aktiengesellschaft (DE) 1985-09-18 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240147927-A1 METHODS OF HIGH PRODUCTION OF POLYPHENOLS FROM RED LETTUCES AND USES THEREOF LCT, ACE2, MYB SMN1; SMN2 4120/4885LMNA 2528/4885TSHR 4305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback